Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)

Inclusion Criteria: * Gestational age \>16 weeks (determined by LMP and fundal height)- if there is discordance between the two, the more conservative estimate (i.e. lower) will be used, to prevent accidental exposure of a 1st trimester fetus * Normal fetal heart beat detected by Doppler * Presence of asexual P. vivax parasitemia ≤ 50,000 parasites/microliter (thick smear) * Willing to sign or thumb print informed consent * Willing to return for scheduled follow up visits for treatment and observation until delivery * Willing to deliver in health facility Exclusion Criteria: * Pregnancy \< 16 weeks * Microscopically confirmed P. falciparum or mixed infection/ parasitemia (P. vivax and another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae) * History of allergy or hypersensitivity to interventional drugs * Exposure to antimalarial drugs and other drugs with antimalarial activity within the past 2 months, as determined by history from the woman (quinine, mefloquine, or artemisinin derivatives, including AL and MA) * Patients taking drugs with possible interaction with study drugs (ie. warfarin, digoxin) * History or family history of epilepsy or psychiatric disorder * Presence of signs and symptoms of severe malaria, severe illness, or danger signs * Hemoglobin \< 7 g/dl * Inability to tolerate oral medication (repeated vomiting, impairment of consciousness). * History of chronic disease including diabetes, renal failure, hepatic failure, heart disease requiring anti-arrhythmic drugs or warfarin, HIV/ AIDS, known hemoglobinopathy * Participant's inability to return for follow up visits * Age \<15 years